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Abstract
Background: Treatments for cancer spinal metastasis were always palliative. This study was
conducted to investigate the safety and effectiveness of IG-IMRT for these patients.
Methods: 10 metastatic lesions were treated with conventionally-fractionated IG-IMRT. Daily
kilovoltage cone-beam computed tomography (kV-CBCT) scan was applied to ensure accurate
positioning. Plans were evaluated by the dose-volume histogram (DVH) analysis.
Results: Before set-up correction, the positioning errors in the left-right (LR), superior-inferior
(SI) and anterior-posterior (AP) axes were 0.3 ± 3.2, 0.4 ± 4.5 and -0.2 ± 3.9 mm, respectively.
After repositioning, those errors were 0.1 ± 0.7, 0 ± 0.8 and 0 ± 0.7 mm, respectively. The
systematic/random uncertainties ranged 1.4–2.3/3.0–4.1 before and 0.1–0.2/0.7–0.8 mm after
online set-up correction. In the original IMRT plans, the average dose of the planning target volume
(PTV) was 61.9 Gy, with the spinal cord dose less than 49 Gy. Compared to the simulated PTVs
based on the pre-correction CBCT, the average volume reduction of PTVs was 42.3% after online
correction. Also, organ at risk (OAR) all benefited from CBCT-based set-up correction and had
significant dose reduction with IGRT technique. Clinically, most patients had prompt pain relief
within one month of treatment. There was no radiation-induced toxicity detected clinically during
a median follow-up of 15.6 months.
Conclusion: IG-IMRT provides a new approach to treat cancer spinal metastasis. The precise
positioning ensures the implementation of optimal IMRT plan, satisfying both the dose escalation
of tumor targets and the radiation tolerance of spinal cord. It might benefit the cancer patient with
spinal metastasis.
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Background
Spine is the most common place of cancer metastasis,
especially for lung cancer and breast cancer. Each year,
approximately 50,000 patients with cancer develop spinal
metastasis worldwide and the 5-year over-all survival rate
of these patients was less than 5% [1,2]. All together,
accompanying with the improvement of therapy for
malignant tumors, the overall survival time of cancer
patients prolonged and the incidence of spinal metastasis
was increasing gradually. Radiotherapy is the standard
treatment for vertebral metastasis of patients with cancer.
Reviewing the literatures, three treatments/fractions were
applied clinically worldwide: 30 Gy/10 fractions, 20 Gy/5
fractions and 8 Gy/1 fraction [3,4]. But all three treat-
ments were palliative, and recurrences in pre-irradiated
foci were frequent. Especially for those patients who only
had vertebral metastasis with primary lesion controlled,
higher dose may increase the local control and survival
possibility of such patients.
To avoid radiation necrosis, the conventionally-fraction-
ated radiotherapy always prescribed no more than 50 Gy
on metastatic sites that were often insufficient to achieve
acceptable local disease control and only inhibit tumor
growth. The more conformal dose distribution of inten-
sity-modulated radiation therapy (IMRT) may provide
satisfactory dose coverage of tumor and avoid excessive
radiation of surrounding normal tissue, therefore with
potential advantage to achieve higher therapeutic ratio.
However the vertebral metastasis was often adjacent to
spinal cord and the sharp dose gradients between PTV and
spinal cord requires high precision of daily positioning to
guarantee implementation of IMRT. Without special tech-
niques that allow highly accurate set-up and dose escala-
tion, some patients who might benefit from radiotherapy
may remain untreated or may be treated with doses
unlikely to provide long-term local control.
So far, surgery is usually offered to patients with a reason-
able life expectancy, whose spinal instability was present
and was causing symptoms [5,6]. Surgery also has been
used for more aggressive and relatively radio-resistant
tumors. Also, the stereotactic radiosurgery is another
choice for those patients. A few study reported that the
single- or hypo-fractionated radiosurgery had the promis-
ing results in the treatment for cancer spinal metastasis [7-
10]. But in practice, the treatment failures were still com-
mon [11,12].
To date, no ideal treatment could be prescribed for these
cancer patients. The newly developed Elekta Synergy™ is
an integrated image-guided radiotherapy (IGRT) system
with the kV-CBCT system attached to a digitalized medical
linear accelerator that can provide onboard CBCT imaging
of set-up errors. Thus, it had been stated as a potential
treatment for cancer spinal metastasis. In this paper, we
report the preliminary results of the application with this
technique, giving details about the safety and effectiveness
of IMRT dose escalation with IGRT for metastatic tumors
of the spinal vertebra.
Methods
Patient selection
This study was carried out in Tumor Center at West China
Hospital, Sichuan University, PR. China. Between May
and November 2006, 9 previously treated cancer patients
with confirmed diagnosis of ≤ 2 spinal metastases and no
other distant metastasis were recruited in this study. The
basic and clinical characteristics of these patients were
shown in Table 1. Each diagnosis was confirmed by com-
puted tomography (CT), magnetic resonance imaging
(MRI) or positron emission tomography-CT (PET-CT)
before the treatment. And KPS scores of the patients were
≥ 80 when admitted in our hospital, with life expectancy
of more than 6 months. This study was carried out with
the approval of West China Hospital's ethics committee.
Treatment planning and evaluation
Each patient underwent spiral CT simulation with 3-mm
slice thickness with vacuum mattress (Stereotactic Body
Frame, Elekta, UK) immobilization. Target volumes and
normal structures were contoured by radiation physi-
cians. The gross target volume (GTV) represented areas at
cancer metastatic parts of vertebra based on pre-planning
CT, MRI or PET-CT imaging. If the whole vertebra was
involved, the clinical tumor volume (CTV) was defined as
equal to GTV; otherwise a 10 mm margin around GTV was
added to generate CTV. For PTV, a 3 mm margin was
added isotropically to CTV, and the PTV was not allowed
to overlap with the adjacent spinal cord but could touch
it. The spinal canal was contoured as a critical structure
and to extend 2 cm length in SI direction beyond the level
of PTV, with a median length of 11.6 cm (range of 8.1–
13.4 cm) in planning. Depending on the metastatic sites,
the lung, right/left kidney, and liver were delineated as
other OAR. All target delineations were reviewed by three
physicians and brought to the final consensus. The IMRT
plan was generated using 9–12 axial beam angles using
aperture-based inverse planning system (PrecisePLAN
Release 2.11, Electa, Sweden). A dose of 60–64 Gy was
prescribed to PTV in 29–31 fractions, and the planning
was to deliver the prescribed dose to at least 95% of the
PTV with a dose range not exceeding -10% and +15% of
the prescribed dose. The dose to spinal cord was restricted
within 50 Gy. The minimum segment size was 2 cm2 with
a minimum of 4 monitor units (MU), a median of 43
(35–55) segments were planned. Segments were manu-
ally adjusted after aperture-based optimization to increase
the dose gradient between target and OAR in 3 patients.Radiation Oncology 2008, 3:11 http://www.ro-journal.com/content/3/1/11
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All plans were evaluated according to DVH analysis. The
homogeneity index (HI) was defined as D5/D95 (mini-
mum dose in 5% of the PTV/minimum dose in 95% of
the PTV). The lower (closer to 1) the HI is, the better the
dose homogeneity. Also, the conformity index (CI) was
calculated as follows: CI = CF (cover factor)·SF (spill fac-
tor), where the CF was defined as the percentage of the
PTV volume receiving the prescription dose and the SF as
the volume of the PTV receiving the prescription dose rel-
ative to the total prescription dose-volume (see also
RTOG protocol 9803). The closer the CI value to approach
1, the better the dose conformity is.
IMRT plan was delivered with step-and-shoot technique
utilizing the system's Beam Modulator™ that is an 80-leaf
MLC with a leaf width of 4 mm (at the isocenter).
KV-CBCT imaging
Daily kV-CBCT images were acquired with the Vol-
umeView™ XVI function. The XVI allows acquiring a series
of projected images at different gantry rotation that can be
reconstructed to 3-dimensional volumetric data, cut to
sections and registered to input planning CT for matching.
The parameters for CBCT scan were 100–120 kV, scan
started from 182–260° and ended at 100–180° with the
total imaging dose of 16 mGy per scanning [13], utilizing
medium resolution reconstruction. Each acquisition pro-
cedure (including image reconstruction) lasted 5 minutes.
Daily CBCT images were registered with the planning CT
using automatically bone matching (correlation coeffi-
cient algorithm, Elekta XVI software) to calculate the tar-
get deviations on the LR, SI and AP axis. The ROI for
image registration was limited to the vertebrae on the level
of the PTV. An action level of 2 mm was set for online cor-
rection of translational error. Only the translational errors
of the target which exceed the 2 mm action limit were con-
verted to a respective shift of the treatment table by man-
ual adjustment. Rotational set-up errors were identified
but unable to correct due to limitation of couch move-
ment. If the rotational set-up errors exceed 2°, patient
should be re-positioned immediately. CBCT re-scan
should be applied to ensure action level not exceeded. The
projection of isocenter was marked on the abdominal skin
of each patient to verify the maintenance of patient set-up
accuracy during treatment at the first fraction, and the
patient set-up remained unmovable during the whole
treatment.
The positioning errors were analyzed as described previ-
ously [14]: The mean of all displacements and the stand-
ard deviation (SD) of all displacements of the whole
group of patients were calculated. For each patient indi-
vidually the mean (systematic error) and standard devia-
tion (random error) of all errors were calculated. The
systematic uncertainty Σ is defined as the standard devia-
tion of the systematic errors. The root-mean-square of the
random errors was calculated as σ. Errors were calculated
separately for all three axes (LR, SI and AP).
Simulation of observed patient set-up errors
According to Yan et al [15], PTV margin can be designed
based on a large confidence level (≥ 98%) with a simple
recipe of 2.27 × SD. The margins based on initial set-up
errors and post-correction errors were thus calculated.
Then the calculated PTV margin at initial setup was added
to CTV in three directions in each IMRT plans respectively,
to generate another PTV (PTVpre) when no online correc-
tion was applied. To simulate the impact of online correc-
tion on dosimetry, the isocenter of the original IMRT plan
was shifted towards each OAR with a magnitude that was
equal to the difference between the calculated pre-correc-
tion margin and actual applied margin (3 mm). The dose-
volume parameters of OARs of the original and simulated
IMRT plans were then compared.
Follow-up
Chemotherapy was prescribed after IG-IMRT. And
patients were seen 1 month, and every 3 months after
treatment. The 100 mm Visual Analog Scale (VAS) meas-
ure was used to evaluate the pain of these patients. The
radiation-induced toxicities were assessed with RTOG cri-
teria [16]. The median follow-up of the study patients was
15.6 months (range of 11–19 months).
Results
In treatment planning, the average dose which the PTVs
received was 61.9 Gy, with the maximum dose of 64.6 Gy
and the minimum dose of 58.7 Gy (Figure 1). The average
level of the maximum dose which the adjacent cord
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The maximum, minimum and mean dose of the 10 metastatic lesions (PTV) in treatment plans and the average level Figure 1
The maximum, minimum and mean dose of the 10 metastatic lesions (PTV) in treatment plans and the aver-
age level.
The homogeneity index/dose conformity index and the average level in treatment plans (1, 2, 3..10 represented the number of  the IMRT plans, respectively) Figure 3
The homogeneity index/dose conformity index and the average level in treatment plans (1, 2, 3..10 repre-
sented the number of the IMRT plans, respectively).Radiation Oncology 2008, 3:11 http://www.ro-journal.com/content/3/1/11
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received was 45.9 Gy, with a range of 44.5–49.0 Gy (Fig-
ure 2). Based on the DVH analysis, the average CI was
0.569, with a range of 0.567–0.572 (Figure 3). For HI, the
maximum and the minimum values were 1.122 and
1.117 respectively, with an average value of 1.12 (Figure
3). A representative IMRT plan with radiation isodose
curves was shown in Figure 4. The PTV (red region) was
covered by the 95% curve (58.5 Gy, the green line) of the
prescription dose (60 Gy), and the curve of 47 Gy touched
the adjacent cord.
As shown in Table 2, both systematic (Σ) and random (σ)
uncertainties were markedly reduced after online correc-
tion which ranged 0.1–0.2/0.7–0.8 mm after correction
compared to 1.4–2.3/3.0–4.1 mm before correction. And
the group mean (M) of the setup errors were small both
before and after correction.
According to the calculated pre-correction margins (2.27
× SD) shown in Table 2, the volume of the actual PTV
(PTVreal) in the applied IMRT plans and simulated PTVpre
were shown in Table 3 in details. The average volume of
PTVreal and PTVpre was 77.1 and 133.7 cm3 respectively;
with an average reduction of 42.3% after online correc-
tion. The impact of translational shift of treatment iso-
center towards each OAR on the dose-volume parameters
was shown in Table 4. More notably, the average reduc-
tion in dose-volume parameters of OAR from PTVpre to
PTVreal were 14.8%, 10.7% and 14.5% in the mean dose,
V20 and V12.5 of the lungs; 19.9%, 33.3%, 29.6% and
21.1% in the mean dose, V30, V20 and V10 of the liver;
21.9%, 42.9%, 23.8% and 20.5% in the mean dose, V30,
V20 and V10 of the right/left kidney; 28.2% and 16.7% in
the maximum dose and D5
spine (maximum dose in 5%
volume of the spinal cord) of spinal cord, respectively.
Clinically, grade 1/2 acute radiation-induced skin toxicity
was observed during treatment, and the majority of
patients had prompt pain relief within 4 weeks of treat-
ment. According to their VAS score, the average level was
83 mm (range, 70–90 mm) at the baseline. 4 weeks after
IG-IMRT, the average score decreased to 52 mm, with a
range of 40–62 mm. And at the end of follow-up, the aver-
age VAS score of these patients was 42 mm. 3 months after
treatment, one patient developed progressive metastasis
in the brain, and one developed liver metastasis, but the
regions of the spine treated with IG-IMRT were clinically
stable. No patient developed acute radiation-induced
injury after the treatment. During follow-up, the lower
extremity strength and ambulation of all patients
remained stable and no patients have experienced compli-
cations as a result of the procedure.
Discussion
The irradiation tolerance of the spinal cord, the TD5/5, is
considered to be in the range of 50 Gy for single daily frac-
tions of 1.8–2.0 Gy [17]. The dose required for cure of a
cancer spinal metastasis should be analogous to that of
the primary site, which generally should not be less than
60 Gy (1.8–2.0 Gy/fraction) for solid tumors. Obviously
the standard conventionally-fractionated 30–40 Gy was
insufficient for long-last control of the spinal metastasis,
resulted in the infield failure to be 26% or more [18]. Sev-
eral studies had been reported using single/hypo-fraction-
ated radiosurgery for cancer spinal metastases [7-12].
According to the linear quadratic formula [19], the bio-
logical-effective-dose (BED) of the metastatic lesions
received in these studies was between 60–153 Gy10. The
clinical outcome indicated that radiosurgery was effective
in the treatment of these patients, improving long-term
palliation. However, the efficacy and safety of radiosur-
gery is limited by tumor volume and the closeness of tar-
gets to the critical organs, for larger tumors the dose is
often reduced to avoid radiation-induced necrosis.
Another limitation inherent of radiosurgery is that it
delivers radiation over a single session and thus does not
encounter multiple mitotic phases, which may spare the
cells staying in the radioresistant phases and increases risk
of recurrence especially with reduced dose [20]. Recently,
improvement in radiation technique provides potential
means of IMRT dose escalation for spinal metastasis can-
cer. Thus for the first time, conventionally-fractionated
radiotherapy with daily CBCT online correction was
applied for cancer spinal metastasis in this study: the BED
was in a range of 97–107 Gy10 for the metastatic lesions
and the irradiation dose of the spinal cord was less than
49 Gy in 29–31 fractions. Comparing to the data from
radiosurgery, a therapeutic dose was prescribed for tumor
The maximum dose of the spinal cord in treatment plans and  the average level Figure 2
The maximum dose of the spinal cord in treatment 
plans and the average level.Radiation Oncology 2008, 3:11 http://www.ro-journal.com/content/3/1/11
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target with IMRT plan, guaranteeing the irradiation toler-
ance of the spinal cord. Follow-up showed no patient suf-
fering from the radiation-induced necrosis as a result of
the treatment and all patients had varying degrees of pain
relief. The average VAS scores of these patients were 83, 52
and 42 mm before, 4 weeks after IG-IMRT and at the end
of follow-up, respectively. Complete pain relief was
observed in 3 patients, and the remaining 6 patients were
able to reduce pain medication. The result was similar
with those from radiosurgery and more superior to the
palliative radiotherapy in such patient. Clinically, the
treatment was effective in the studied population.
Due to the steep dose gradients between metastatic
lesions and spinal cord of the IMRT plan, very precise set-
up procedure before radiotherapy is necessary. With the
application of IGRT technique, patient set-up accuracy
was verified by in-room CT scanner, helical tomotherapy,
orthogonal X-ray cameras, and CT on rail in radiotherapy
for spinal or paraspinal cancer [12,21-24]. Basically, sim-
ply applying the patient immobilizing technique with
wall laser marks on the body surface still can not fulfill the
stringent target position requirement of high precision
radiotherapy. In this study, daily CBCT with online cor-
rection of set-up errors before treatment was practiced to
A representative IMRT plan with radiation isodose curves Figure 4
A representative IMRT plan with radiation isodose curves. The PTV (red region) was covered by the 95% curve of the 
prescription dose (the green line), and the dose of the adjacent cord was less than 49 Gy. (a: transverse section and b: sagittal 
section).
Table 2: The positioning errors before/after (without/with) online set-up correction in the LR, SI and AP axes in this study (mm)
LR SI AP
Before After Before After Before After
mean 0.3 0.1 0.4 0.0 -0.2 0.0
SD 3.2 0.7 4.5 0.8 3.9 0.7
Range -12.0 ~ 13.5 -2.6 ~ 1.4 -17.2 ~ 16.3 -2.5 ~ 1.5 -12.9 ~ 10.9 -1.9 ~ 1.5
Σ 1.4 0.2 2.1 0.2 2.3 0.1
σ 3.0 0.8 4.1 0.7 3.2 0.7
Theoretic margin 7.4 1.7 10.2 1.6 8.8 1.7
Translational shift 4.4 7.2 5.8
Before: before online set-up correction; After: after online set-up correction; Theoretic margin: calculated by 2.27 × SD based on a pre-selected 
confidence level of 98%; Translational shift: translational shift of the treatment isocenter in simulated IMRT plan to cover the theoretic margin 
without online set-up correction in three axes, and calculated as "theoretic margin before online set-up correction-3" mm.Radiation Oncology 2008, 3:11 http://www.ro-journal.com/content/3/1/11
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achieve the maximum accuracy and safety for the patient.
The systematic/random errors at initial set-up were 1.4/
3.0, 2.1/4.1 and 2.3/3.2 mm in the LR, SI and AP axes,
respectively. After set-up correction, those errors were 0.2/
0.8, 0.2/0.7 and 0.1/0.7 mm in the three axes respectively,
indicating the role of online correction on improving
positioning precision for radiotherapy of spinal meta-
static cancer, thus may potentially reduce the adverse
effect of set-up errors on tumor control probability and
normal tissue complication probability (NTCP) in radio-
therapy treatment [25].
Based on the margin-calculating recipe, a 1.7, 1.6 and 1.7
mm margin should be added to the CTV for generating
PTV in the LR, SI and AP axes respectively with CBCT
online correction, confirming that the 3 mm region
around the GTV/CTV was enough and acceptable with
CBCT-based guidance. Without online correction, the cal-
culated margins in the three axes were 7.4, 10.2 and 8.8
mm, respectively. In each IMRT plan, we simulated the
hypothetic effects of the pre-correction positioning errors
on PTV and dose-volume parameters of OAR. As shown in
Table 3, the reduction of volume from the pre-correction
PTVpre to the PTVreal with online correction was considera-
Table 3: The volumes of original and simulated PTVs in this study (cm3)
Target number PTVreal PTVpre Volume reduction from PTVpre to PTVreal (%)
1 15.6 26.4 40.9%
2 94.7 168.6 43.8%
3 82.5 126.2 34.6%
4 89.3 150.6 40.7%
5 72.6 116.4 37.6%
6 18.9 37.2 49.2%
7 108.4 204.3 46.9%
8 91.2 155.8 41.4%
9 112.3 221.2 49.2%
10 85.9 130.6 34.2%
Average 77.1 133.7 42.3%
PTVreal: actual PTV in the original IMRT plans; PTVpre: simulated PTV based on the theoretic margins in three axes without online set-up 
correction.
Table 4: Average normal tissue dose-volume parameters based on PTVpre and PTVreal in each original and simulated IMRT plans
Normal tissue parameter Average parameters based on PTVpre Average parameters based on 
PTVreal
Average parameters reductions from 
PTVpre to PTVreal (%)
Lung (n = 4)
Maximum dose 57.3 Gy 55.2 Gy 3.7
Average dose 10.8 Gy 9.2 Gy 14.8
V20 12.2% 10.9% 10.7
V12.5 23.5% 20.1% 14.5
Liver (n = 4)
Maximum dose 58.6 Gy 56.1 Gy 4.3
Average dose 14.6 Gy 11.7 Gy 19.9
V30 12% 8% 33.3
V20 27% 19% 29.6
V10 38% 30% 21.1
kidney (n = 4)
Maximum dose 60.2 Gy 57.8 Gy 4.0
Average dose 14.6 Gy 11.4 Gy 21.9
V30 7% 4% 42.9
V20 21% 16% 23.8
V10 39% 31% 20.5
Cord (n = 10)
Maximum dose 68.4 Gy 49.1 Gy 28.2
Average dose 34.3 Gy 31.2 Gy 9.1
D5spine 54.4 Gy 45.3 Gy 16.7
PTVpre: simulated PTV based on the theoretic margins in the three axes without online set-up correction; PTVreal: actual PTV in the original IMRT 
plans; D5spine: maximum dose in 5% volume of the spinal cord.Radiation Oncology 2008, 3:11 http://www.ro-journal.com/content/3/1/11
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ble, with an average level of 42.3%. Also, the translational
shift of isocenter towards each OAR had significant
impact on the dose-volume parameters of these organs.
Depending on the target location, there were 4 targets
related to lung, 4 targets related liver and right/left kidney,
and 10 targets related to spinal cord. The dose-volume
parameters of each OAR were reduced to varying degrees.
The dose reductions could translate clinically into a lower
probability of treatment toxicity, as well as a potential
increase in the number of patients that might be eligible
for IG-IMRT or concurrent chemoradiotherapy.
The spinal cord was the key OAR in this study. The iso-
center was shifted in the six directions (moving left/right,
Comparison of the simulated effects of the positioning errors with/without CBCT-based online set-up correction in the LR, SI  and AP axes on the irradiation dose of the spinal cord with the actual plan (red and orange line: isocenter moving left/right in  LR axis, yellow and deep green lines: isocenter moving superior/inferior in SI axis, blue and purple lines: isocenter moving ante- rior/posterior in AP axis, respectively; and the green line was the actual DVH of the cord) Figure 5
Comparison of the simulated effects of the positioning errors with/without CBCT-based online set-up correc-
tion in the LR, SI and AP axes on the irradiation dose of the spinal cord with the actual plan (red and orange 
line: isocenter moving left/right in LR axis, yellow and deep green lines: isocenter moving superior/inferior in SI 
axis, blue and purple lines: isocenter moving anterior/posterior in AP axis, respectively; and the green line was 
the actual DVH of the cord). (a: the simulated and actual DVHs of the cord and b: the simulated and actual maximum dose 
of 5% volume of the cord).Radiation Oncology 2008, 3:11 http://www.ro-journal.com/content/3/1/11
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inferior/superior, and anterior/posterior in LR, SI and AP
axes) respectively to simulate the impact of pre-correction
margin on the dose-volume parameters of the spinal cord.
Figure 5 showed the simulated and original DVH of the
spinal cord in one IMRT plan (the same patient as Figure
4 represented). The position errors in SI axes had little
impact on the irradiation dose of the cord. As well, it indi-
cated that the D5
spine changed significantly, if position
errors occurred towards the cord in LR and AP axis, respec-
tively. Most significantly, the posterior shift towards the
cord resulted in a maximum dose of 68 Gy to the cord.
Comparing to the results reported by Guckenberger et al
[26], our study suggested that without the CBCT online
guidance, the IMRT plan could not be applied successfully
in such patients.
Although only the inter-fractional setup errors was taken
into account as the major source of uncertainties to affect
the accuracy of IMRT dose delivery in this study, there was
another important factor which also contribute to the
dose delivery accuracy: movement of the target and spinal
cord during treatment (intra-fraction variation). First, CTV
for the paraspinal lesions was assumed to be fixed to the
vertebrae and the intra-treatment motion of the target
would be equivalent to the motion of the spinal column.
Data from literatures have confirmed that in conformal
radiotherapy, intra-fraction organ/target motion can be
achieved in the range of 1 mm with proper immobiliza-
tion [21,27]. Second, Cai et al found that the spinal cord
motion during normal breathing was typically within 0.5
mm by dynamic MRI (dMRI), and partly stated that the
spinal cord was almost immovable during breathing [28].
Third, studies in Massachusetts General Hospital and
Memorial Sloan-Kettering Cancer Center indicated that
the effects of intra-fraction organ motion on IMRT dose
delivery were ignorable in a typical treatment with 30 frac-
tions in breast and pulmonary radiotherapy [29,30].
Obviously, for the more fixed OAR (spinal cord) in the
vacuum mattress, the effects of intra-fraction organ
motion would be more minimal in this conventionally-
fractionated IMRT therapy. In addition, all target delinea-
tions were reviewed by three physicians together, dimin-
ishing the impact of the delineation-induced variation on
the geometrical accuracy in conformal radiotherapy [31-
33] as far as possible. Consequently, as discussed previ-
ously, the precise patient set-up with CBCT online correc-
tion was the minimal requirement and meaningful factor
in dose delivery accuracy of IG-IMRT in this study.
Limitation in this study should be addressed here. The
position errors should include not only the translational
set-up errors, but also the rotational errors, which may
have effect on the accuracy of dose delivery. A few studies
evaluated the rotational set-up errors in conformal radio-
therapy for spinal diseases [26,34]. Due to the limitation
of the treatment couch, patient in our study should be re-
positioned if the rotational set-up errors exceeded 2°. So,
the rotational set-up errors and their impact on IMRT dose
delivery had not been evaluated in this study.
Conclusion
Therefore, this study presented the preliminary data to
demonstrate the safety and effectiveness of this technique
in treatment of patients with cancer spinal metastasis.
These results are encouraging. Although the studied sam-
ple size was somewhat small and with the limitation men-
tioned above, it still was a hopeful progress in radiation
therapy for patient with cancer. As a result, the application
of conventionally-fractionated IG-IMRT has the potential
to improve the clinical outcome of the patients with can-
cer spinal metastasis.
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